Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alterations of platelet function induced by interleukin-2.

L Oleksowicz1, P A Paciucci, D Zuckerman

  • 1Jeanne B. Lambert Laboratory for Cancer Research, Department of Neoplastic Diseases, Mount Sinai Medical Center, New York, NY 10029.

Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|October 1, 1991
PubMed
Summary

Interleukin-2 (IL-2) immunotherapy can cause bleeding by affecting platelets. IL-2 activates mononuclear cells, which then cause platelet secretion and inhibit aggregation, impacting immune system and hemostasis understanding.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The relationship between miscommunication and medical malpractice.

The Florida nurse·2002
Same author

Screening for breast cancer with mammography.

Lancet (London, England)·2002
Same author

Commentary: are breast implants safe?

MedGenMed : Medscape general medicine·2001
Same author

Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.

Clinical & experimental metastasis·2000
Same author

Interleukin-2 plus chemotherapy for patients with metastatic melanoma.

Melanoma research·2000
Same author

PAR, a novel androgen regulated gene, ubiquitously expressed in normal and malignant cells.

International journal of oncology·2000

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Background:

  • Interleukin-2 (IL-2) immunotherapy is associated with thrombocytopenia and bleeding.
  • The mechanisms underlying IL-2-induced platelet toxicity are not fully understood.

Purpose of the Study:

  • To investigate the in vitro effects of IL-2 on platelet function.
  • To elucidate the cellular mechanisms responsible for IL-2-mediated platelet dysfunction.

Main Methods:

  • Whole blood aggregometry was used to assess platelet aggregation.
  • Platelet secretion was quantified using radioimmunoassay (RIA) for specific markers.
  • Mononuclear cells were depleted and reconstituted to determine their role in IL-2 effects.
  • Eicosanoid products, including TXB2, were measured in IL-2-stimulated mononuclear cell cultures.

Related Experiment Videos

Main Results:

  • IL-2 directly inhibited platelet aggregation in whole blood within one minute.
  • IL-2 induced platelet secretion of PF4, BTG, and TXB2 independently of aggregation agonists.
  • These effects were mediated indirectly by mononuclear cells, which released increased TXB2 upon IL-2 activation.
  • Mononuclear cell depletion abrogated IL-2's effect on aggregation, which was restored upon cell reconstitution.

Conclusions:

  • IL-2 immunotherapy leads to platelet secretion and aggregation inhibition indirectly via activated mononuclear cells.
  • This interaction highlights a novel link between the immune and hemostatic systems.
  • Findings have implications for managing IL-2 immunotherapy clinical trials and understanding immune-hemostatic interactions.